ProteomEdge–SEVERAL: investment, 202603 2nd financing round SEK8m led by Navigare Ventures + incl existing investors

	Period	2026-03-25
	Predecessor	ProteomEdge–SEVERAL: investment, 202505 financing round SEK7.8m led by Navigare Ventures + incl existing investors
	Money taker	ProteomEdge AB
	Money source	SEVERAL
	Product	DiscoveryEdge™600 labeled protein standards panel (ProteinEdge)
	Product 2	venture capital
	Person	Almstedt, Elin (Wallenberg 202603 Principal at Navigare Ventures)

ProteomEdge AB. (3/25/26). "Press Release: ProteomEdge Raises SEK 8 Million in Follow-On Funding and Launches DiscoveryEdge600". Stockholm.

Round led by Navigare Ventures supports commercial expansion and the rollout of ProteomEdge’s latest product encompassing the largest panel of internal standards for absolute quantification with mass spectrometry.

ProteomEdge today announced the successful completion of a second funding round of SEK 8 million, led by Navigare Ventures, a subsidiary of Wallenberg Investments AB, with continued strong participation from existing shareholders. The proceeds will support commercial expansion and the rollout of DiscoveryEdge™600.

The follow-on round matches the size of the company’s previous financing and reflects continued investor confidence in ProteomEdge’s strategy, technology and commercial progress. The financing comes as ProteomEdge launches DiscoveryEdge™600, an expanded offering for absolute protein quantification by mass spectrometry. The product broadens the company’s targeted proteomics portfolio for research and translational applications.

“This continued support from our investors is a strong validation of our progress and vision,” said Henrik Everberg, CEO of ProteomEdge. “This financing gives us the resources to accelerate our commercial expansion. With DiscoveryEdge™600 now launched, we are focused on broadening customer access to high-precision absolute protein quantification.”

Professor Mathias Uhlén, Co-founder and Chairman of the Board, added: “The fact that we are securing additional funding from the same committed investors demonstrates a shared long-term belief in ProteomEdge. This investment enables us to further strengthen our product portfolio and scale our commercial presence globally.”

“Navigare Ventures is pleased to continue supporting ProteomEdge in this next phase,” said Elin Almstedt, Principal at Navigare Ventures. “The successful development of DiscoveryEdge600 and the company’s growing commercial traction highlight both execution strength and market relevance. We remain confident in the team’s ability to deliver on its vision and drive continued growth.”

With strong backing from its shareholders and a newly launched flagship product DiscoveryEdge600, ProteomEdge is well-positioned to accelerate its commercial rollout and reinforce its leadership in next-generation blood-based proteomics.

About ProteomEdge

ProteomEdge is a Swedish proteomics company founded in 2023 by researchers from the Human Protein Atlas program and Science for Life Laboratory (SciLifeLab) in Stockholm. The company develops proprietary mass spectrometry-based solutions for absolute protein quantification, enabling precise and scalable measurement of clinically relevant proteins. ProteomEdge’s product portfolio supports biomarker research and translational applications in blood-based proteomics.

For more information, please contact:

Henrik Everberg CEO, ProteomEdge
henrik.everberg@proteomedge.com
+4673-503 96 96